Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Infliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitis.

Raza K, Carruthers DM, Stevens R, Filer AD, Townend JN, Bacon PA.

Ann Rheum Dis. 2006 Jul;65(7):946-8. Epub 2005 Dec 16.

2.

Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation.

Booth AD, Jayne DR, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, Wilkinson IB.

Circulation. 2004 Apr 13;109(14):1718-23. Epub 2004 Mar 22.

3.

Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients.

Sidiropoulos PI, Siakka P, Pagonidis K, Raptopoulou A, Kritikos H, Tsetis D, Boumpas DT.

Scand J Rheumatol. 2009 Jan-Feb;38(1):6-10. doi: 10.1080/03009740802363768.

PMID:
18991190
4.

Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.

Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA.

Arthritis Rheum. 2008 Dec 15;59(12):1821-4. doi: 10.1002/art.24308.

5.

Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.

Cardillo C, Schinzari F, Mores N, Mettimano M, Melina D, Zoli A, Ferraccioli G.

Clin Pharmacol Ther. 2006 Sep;80(3):275-81.

PMID:
16952494
6.

Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.

Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J.

Clin Exp Rheumatol. 2006 Jul-Aug;24(4):373-9.

PMID:
16956426
7.

Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody.

Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA.

Arthritis Rheum. 2004 Jun 15;51(3):447-50.

8.

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.

Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J.

Arthritis Rheum. 2000 Jun;43(6):1346-52.

9.
10.

Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab.

Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A, Garcia-Porrua C, Martin J, Gonzalez-Gay MA.

Clin Exp Rheumatol. 2006 May-Jun;24(3):309-12.

PMID:
16870100
11.

Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis.

Komai N, Morita Y, Sakuta T, Kuwabara A, Kashihara N.

Mod Rheumatol. 2007;17(5):385-90. Epub 2007 Oct 19.

PMID:
17929130
12.

Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis.

Puéchal X, Miceli-Richard C, Mejjad O, Lafforgue P, Marcelli C, Solau-Gervais E, Steinfeld S, Villoutreix C, Trèves R, Mariette X, Guillevin L; Club Rhumatismes et Inflammation (CRI).

Ann Rheum Dis. 2008 Jun;67(6):880-4. Epub 2007 Nov 23.

PMID:
18037625
13.

Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica.

Karppinen J, Korhonen T, Malmivaara A, Paimela L, Kyllönen E, Lindgren KA, Rantanen P, Tervonen O, Niinimäki J, Seitsalo S, Hurri H.

Spine (Phila Pa 1976). 2003 Apr 15;28(8):750-3; discussion 753-4.

PMID:
12698115
15.

Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade.

Kleinert J, Lorenz M, Köstler W, Hörl W, Sunder-Plassmann G, Soleiman A.

Wien Klin Wochenschr. 2004 May 31;116(9-10):334-8.

PMID:
15237661
16.
17.

Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis.

Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Béchir M, Spieker LE, Neidhart M, Michel BA, Gay RE, Lüscher TF, Gay S, Ruschitzka F.

Circulation. 2002 Oct 22;106(17):2184-7.

18.

Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behçet disease.

Ribi C, Sztajzel R, Delavelle J, Chizzolini C.

J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1733-5.

19.

Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.

Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J.

Clin Exp Rheumatol. 2006 Jan-Feb;24(1):83-6.

PMID:
16539824
20.

Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study.

Sandoo A, van Zanten JJ, Toms TE, Carroll D, Kitas GD.

BMC Musculoskelet Disord. 2012 Jul 23;13:127. doi: 10.1186/1471-2474-13-127.

Items per page

Supplemental Content

Write to the Help Desk